NEW YORK – Molecular diagnostics firm Co-Diagnostics announced Friday that it has entered into a definitive agreement with institutional investors to purchase its stock in a direct offering.
The Salt Lake City, Utah-based firm will sell about 3.5 million shares of its common stock, at $1.45 per share. The offering is expected to close on or about Jan. 28.